[Click e-Stock] "Kolon TissueGene's TG-C Valued at 8.3 Trillion Won"

On September 12, Korea Investment & Securities analyzed that the value of Kolon TissueGene's cell and gene therapy for osteoarthritis, TG-C, amounts to 8.3 trillion won.

Researcher Haejoo Wi of Korea Investment & Securities explained, "The estimated wholesale price of TG-C is $25,000. Since the efficacy of a single injection lasts for two years, the annual wholesale price is $12,500."

He added, "We estimated the drug price by reflecting TG-C's safety, pain reduction, improvement in function, and delay in artificial joint surgery, as confirmed through clinical trial results and long-term follow-up data."

He emphasized, "If it is prescribed to 8% of eligible patients, or 400,000 people, in 2041, sales will reach 13 trillion won and net profit will amount to 7.2 trillion won."

Researcher Wi analyzed, "The announcement of phase 3 clinical trial results in June or July next year will be a major growth driver. The phase 3 clinical trial is showing strong potential for success in the U.S. osteoarthritis new drug market, which has a large patient pool and no competing drugs." He further predicted, "The current market capitalization is only 3.8 trillion won, and TG-C is expected to achieve a meaningful initial market share of 0.5% in the U.S. market by 2030."

원본보기 아이콘

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.